Skip to main content

Acneiform Eruption Due to Chemical

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Hoth Therapeutics
Hoth TherapeuticsNY - New York
1 program
1
HT-001 2% Topical GelPhase 21 trial
Active Trials
NCT05639933Recruiting152Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Hoth TherapeuticsHT-001 2% Topical Gel

Clinical Trials (1)

Total enrollment: 152 patients across 1 trials

NCT05639933Hoth TherapeuticsHT-001 2% Topical Gel

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Start: Jul 2023Est. completion: Dec 2026152 patients
Phase 2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 152 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.